Physician profile
Anne E Vincent
NPI 1447672464
$3,600.83
in general payments reported to CMS, 2019-2025
24 companies · $939 in 2025
The $939 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $482 · 2022: $460 · 2023: $923 · 2024: $796 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,658.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,741.92 | 2021-2025 | Spravato |
| Abbvie INC. | $707.90 | 2021-2025 | |
| Astellas Pharma US INC | $133.76 | 2024-2025 | Veozah |
| Corium, LLC | $122.89 | 2023 | Azstarys |
| Braeburn INC. | $119.88 | 2023-2025 | Brixadi |
| Idorsia Pharmaceuticals US INC | $106.59 | 2023-2024 | Quviviq |
| Alkermes, INC. | $106.31 | 2025 | Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.40 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $67.48 | 2023-2025 | Auvelity |
| Indivior INC. | $58.04 | 2021-2025 | Sublocade |
| Organon LLC | $49.75 | 2024-2025 | Nexplanon |
| Hikma Pharmaceuticals USA | $34.80 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $32.94 | 2021-2022 | |
| Lilly USA, LLC | $32.66 | 2021 | |
| Exeltis, USA INC. | $29.41 | 2024 | Slynd |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $25.12 | 2024 | Rybelsus |
| Neurocrine Biosciences, INC. | $24.50 | 2025 | |
| Vanda Pharmaceuticals INC. | $21.76 | 2021 | |
| Boston Scientific Corporation | $21.27 | 2023 | |
| Inspire Medical Systems, INC. | $18.33 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $14.82 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.48 | 2023 | Tradjenta, Synjardy |
| Eisai INC. | $13.68 | 2021 | |
| Lucid Diagnostics INC. | $13.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Vincent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.